What is the primary profit strategy associated with the CRISPR gene-editing technology cluster?
Answer
Licensing the fundamental tool itself to every research lab and pharmaceutical company utilizing the method.
The immense potential value of CRISPR technology stems not just from creating specific end-products, but from owning the core methodology that facilitates genome editing. The profit mechanism relies heavily on licensing this powerful *tool* broadly. Any research lab, agricultural firm, or pharmaceutical company wishing to utilize precise genome editing must secure a license for the method, creating a steady stream of royalty payments based on usage across medicine, agriculture, and fundamental research.
Related Questions
Why is the Texas Instruments microprocessor patent frequently cited for its near-infinite indirect value?What governing terms are essential patents for 4G and 5G wireless standards often required to be licensed under?How does the licensing revenue potential of a broad method patent compare to one protecting a single physical product?What factor typically anchors blockbuster pharmaceutical patents as contenders for the most valuable single patent?What is the primary profit strategy associated with the CRISPR gene-editing technology cluster?Which mechanical innovation, crucial for affordable digital storage, is highlighted as underpinning data centers and personal computers?What is the purpose of 'evergreening' concerning pharmaceutical compositions patents?What does the comparison between the digital camera sensor patent and a specific video compression patent illustrate about patent breadth?What distinction is critical when assessing the historical profitability of patents that were not widely commercialized?How do defensive patents held in a company's portfolio, like those in semiconductors, generate value without asserting commercial use?